0      0

JL1106ES - JL1106ES: Comparative Real-world (RW) Evidence on Darolutamide (Daro), Enzalutamide (Enza), and Apalutamide (Apa) for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) Patients (Pts) in the United States (DEAR)

‐ Oct 30, 2023 11:00am

Full author listing

Alicia K. Morgans, MD1 Neal D. Shore, MD2 Nasreen Khan, PhD3 Niculae Constantinovici, MD4 Javeed Khan, MSc5 Guifang Chen, MSc3 Julie Xu, MSc6 Jorge Ortiz, MD3 Daniel J. George, MD7

1Dana-Farber Cancer Institute, Boston, MA, USA; 2Carolina Urologic Research Center, Myrtle Beach, SC, USA; 3Bayer HealthCare, Whippany, NJ, USA; 4Bayer Consumer Care AG, Basel, Switzerland; 5Bayer plc, Reading, United Kingdom; 6Bayer Canada, Mississauga, ON, Canada; 7Duke University Cancer Institute, Durham, NC, USA


You must be logged in and own this session in order to post comments.